Fundamental Analysis of Merck & Company Inc - Growth / Value Index


MRK - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Good Score of 67.19
   Undervalued - Price to Intrinsic Value of 0.198
   Price to Earning Ratio is 12.31 and EV to EBITDA is 9.79 suggesting company is undervalued.
   Book Value in last 3 years is trending up
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 12.31 13.79 -97.87 %
Price to Book 3.43 1.94 -69.18 % 5.63
Price to Sales 3.65 3.68 -6.54 %
Enterprise Value to EBITDA Multiple 9.79 9.65 -76.26 %


MRK - Profitability Highlights

Profitability Analysis

   Tsr Profitability Index - Excellent Score of 85.00
   Piotroski F Score - Excellent Value of 8.0
   Earning Yield of 8.13 %
   Excellent QoQ /QoQ FY EPS growth
   Company Earning excess return
   During the past twelve months, the company has given a strong Return On Equity of 39.95%
   During the past twelve months, the company has given a strong Net Margin of 29.63%
   All key Trailing Twelve Months Margin growing by 15 %
   Reasonable Dividend Yield of 3.69 %
   Annual Net Profit in last 3 years is trending up
   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   EBITDA is continuously increasing for last 3 Years
   Steady Growth in EPS for last four quarters
   Good Return On Capital Employed of 20.54
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 39.95 38.41 3855.10 % 11.16
Return On Asset 17.36 22.15 6373.12 % 5.20
Net Profit Margin 29.63 26.68 4293.38 % 33.49
Operating Profit Margin 39.41 35.36 619.66 % 43.74
EBITDA Margin 40.46 41.98 265.40 % 39.04


Highlights
Market Cap230629 M
Enterprise Value254498 M
Price/Book TTM3.43
Outstanding Share2482.02 M
Float/ Outstanding Share99.84%
Dividend Yield3.50 %
Share Holding
Guru Numbers
Price/Graham No1.03
Peter Lynch Ratio373.86
Piotroski F Score8.00
Altman Z Score-0.0135
Sloan Ratio0.0438
Peter Lynch Fair Value82.14


MRK - Growth Highlights

Growth Analysis

   YoY Net Margin Jump by 4293.38%
   Annual sales of the company is increased for three years in a row
   Tsr Growth Index - Poor Score of 28.05
   Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 64235.00 M 6.74 % 9.30 %
Gross Profit 53211.00 M 17.94 % 15.54 %
EBITDA 25987.67 M 290.03 % 34.93 %
Net Profit 19034.00 M 4589.59 % 30.68 %
EPS 7.55 4600.66 % NA


MRK - Stability Highlights

Stability Analysis

   Altman Z Score of -0.0138 suggest high risk
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.833 -11.44 % 0.798
Cash Ratio 0.513 50.38 %
Quick Ratio 0.299 -70.28 % 1.44
Shareholders Equity 57.66 63.66 %
Debt to EBITDA 1.38 -73.08 %


Historical Valuation Ratios of Merck & Company Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Merck & Company Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Merck & Company Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Merck & Company Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)